
ACRV
Acrivon Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.480
Open
1.430
VWAP
--
Vol
354.39K
Mkt Cap
44.84M
Low
1.410
Amount
--
EV/EBITDA(TTM)
--
Total Shares
30.88M
EV
-104.80M
EV/OCF(TTM)
--
P/S(TTM)
--
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. It uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
--
--
-0.567
+4.94%
--
--
-0.580
-1.69%
--
--
-0.583
+12.18%
Estimates Revision
The market is revising Downward the revenue expectations for Acrivon Therapeutics, Inc. (ACRV) for FY2025, with the revenue forecasts being adjusted by -11.11% over the past three months. During the same period, the stock price has changed by -0.69%.
Revenue Estimates for FY2025
Revise Downward

-11.11%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward

-11.83%
In Past 3 Month
Stock Price
Go Down

-0.69%
In Past 3 Month
7 Analyst Rating

616.78% Upside
Wall Street analysts forecast ACRV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACRV is 10.25 USD with a low forecast of 6.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy

616.78% Upside
Current: 1.430

Low
6.00
Averages
10.25
High
19.00

616.78% Upside
Current: 1.430

Low
6.00
Averages
10.25
High
19.00
JonesResearch
Buy
to
Hold
downgrade
2025-05-16
Reason
JonesResearch
Price Target
2025-05-16
downgrade
Buy
to
Hold
Reason
Oppenheimer
Oppenheimer
Outperform
downgrade
$10 -> $9
2025-05-14
Reason
Oppenheimer
Oppenheimer
Price Target
$10 -> $9
2025-05-14
downgrade
Outperform
Reason
Oppenheimer lowered the firm's price target on Acrivon Therapeutics to $9 from $10 and keeps an Outperform rating on the shares. The firm is adjusting its model after the company's Q1 results and updates on its cash and share position, the analyst tells investors in a research note.
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$19
2025-03-28
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$19
2025-03-28
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Maintains
$22 → $19
2025-03-26
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$22 → $19
2025-03-26
Maintains
Strong Buy
Reason
Citizens Capital Markets
Silvan Tuerkcan
Buy
Reiterates
$17
2025-03-26
Reason
Citizens Capital Markets
Silvan Tuerkcan
Price Target
$17
2025-03-26
Reiterates
Buy
Reason
Cantor Fitzgerald
Li Watsek
Buy
Reiterates
n/a
2025-03-26
Reason
Cantor Fitzgerald
Li Watsek
Price Target
n/a
2025-03-26
Reiterates
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Acrivon Therapeutics Inc (ACRV.O) is -0.59, compared to its 5-year average forward P/E of -2.96. For a more detailed relative valuation and DCF analysis to assess Acrivon Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-2.96
Current PE
-0.59
Overvalued PE
-1.31
Undervalued PE
-4.61
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
45.18
Current PS
346.78
Overvalued PS
183.35
Undervalued PS
-92.99
Financials
Annual
Quarterly
FY2025Q1
YoY :
+22.61%
-21.66M
Operating Profit
FY2025Q1
YoY :
+19.37%
-19.68M
Net Income after Tax
FY2025Q1
YoY :
-30.14%
-0.51
EPS - Diluted
FY2025Q1
YoY :
+9.47%
-19.59M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
400.5K
USD
1
3-6
Months
3.4M
USD
4
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 7413.3% over the last quarter.
Sold
0-3
Months
2.3M
Volume
1
3-6
Months
30.1K
Volume
1
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
400.5K
USD
1
3-6
Months
3.4M
USD
4
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ACRV News & Events
Events Timeline
2025-05-14 (ET)
2025-05-14
16:31:10
Acrivon Therapeutics reports Q1 EPS (51c), consensus (65c)

2025-04-25 (ET)
2025-04-25
08:06:59
Acrivon Therapeutics to present data from analyses of ACR-2316 at AACR

2025-04-07 (ET)
2025-04-07
16:07:31
Acrivon appoints Mansoor Raza Mirza as Chief Medical Officer

Sign Up For More Events
Sign Up For More Events
News
5.0
04-07NewsfilterAcrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer
9.5
03-27NewsfilterAcrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results
9.5
03-27Business InsiderAcrivon Therapeutics reports Q4 EPS (60c), consensus (70c)
Sign Up For More News
People Also Watch

ADCT
ADC Therapeutics SA
3.120
USD
-4.88%

UAMY
United States Antimony Corp
3.340
USD
-0.30%

CLAR
Clarus Corp
3.880
USD
-1.27%

STFS
Star Fashion Culture Holdings Ltd
1.810
USD
-2.16%

TRVG
Trivago NV
4.060
USD
+6.56%

HQI
Hirequest Inc
10.280
USD
+0.59%

CCRD
CoreCard Corp
27.890
USD
+2.05%

OXSQ
Oxford Square Capital Corp
2.330
USD
0.00%

KEQU
Kewaunee Scientific Corp
57.350
USD
-2.53%

POWW
Outdoor Holding Company
1.160
USD
-5.69%
FAQ

What is Acrivon Therapeutics Inc (ACRV) stock price today?
The current price of ACRV is 1.43 USD — it has increased 0 % in the last trading day.

What is Acrivon Therapeutics Inc (ACRV)'s business?

What is the price predicton of ACRV Stock?

What is Acrivon Therapeutics Inc (ACRV)'s revenue for the last quarter?

What is Acrivon Therapeutics Inc (ACRV)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Acrivon Therapeutics Inc (ACRV)'s fundamentals?

How many employees does Acrivon Therapeutics Inc (ACRV). have?
